Corient Private Wealth LLC raised its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 601.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 339,848 shares of the company's stock after purchasing an additional 291,425 shares during the period. Corient Private Wealth LLC's holdings in Kenvue were worth $7,256,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also recently made changes to their positions in the company. Handelsbanken Fonder AB increased its stake in Kenvue by 2.9% during the fourth quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company's stock worth $15,846,000 after acquiring an additional 21,222 shares during the last quarter. Alberta Investment Management Corp increased its position in shares of Kenvue by 23.2% during the 4th quarter. Alberta Investment Management Corp now owns 582,895 shares of the company's stock valued at $12,445,000 after purchasing an additional 109,700 shares during the last quarter. Longbow Finance SA raised its holdings in Kenvue by 5.0% during the 4th quarter. Longbow Finance SA now owns 280,568 shares of the company's stock valued at $5,990,000 after buying an additional 13,287 shares during the period. Steward Partners Investment Advisory LLC lifted its position in Kenvue by 143.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company's stock worth $1,023,000 after buying an additional 28,216 shares during the last quarter. Finally, CORDA Investment Management LLC. boosted its stake in Kenvue by 1.4% during the fourth quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company's stock worth $26,754,000 after buying an additional 17,466 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on KVUE. Barclays lowered their target price on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a report on Friday, January 17th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a "buy" rating to a "hold" rating and dropped their target price for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Canaccord Genuity Group increased their price target on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. UBS Group reduced their target price on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Finally, Citigroup lowered their target price on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research note on Wednesday, January 15th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $23.85.
Check Out Our Latest Analysis on Kenvue
Kenvue Stock Down 1.2 %
NYSE:KVUE traded down $0.29 during trading hours on Tuesday, reaching $23.08. The company's stock had a trading volume of 14,987,646 shares, compared to its average volume of 16,155,267. The stock has a 50 day moving average price of $22.13 and a two-hundred day moving average price of $22.44. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market capitalization of $44.11 billion, a P/E ratio of 43.55, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.55%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue's payout ratio is currently 154.72%.
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Articles
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
